添加的内容 删除的内容
小 (机器人:清理不当的来源、移除无用的模板参数) |
小 (机器人:清理不当的来源、移除无用的模板参数) |
||
(未显示另一用户的1个中间版本) | |||
第7行:
| location = [[波士顿]]
| key_people = Jeffrey Leiden(CEO)
| industry = [[制药]]和[[生物技术]]<ref>{{cite web |url=http://www.hoovers.com/company/Vertex_Pharmaceuticals_Incorporated/rhytri-1.html |title=Vertex Pharmaceuticals Incorporated |publisher=[[Hoover's]] |accessdate=2012-06-24
| products =
| revenue = {{profit}} [[美元|US$]]21.7亿(2017)
第16行:
== 历史 ==
1989年由[[约书亚·博格]]<ref name="Globe">{{cite news |title=Rearranging the Corporate DNA |first=Robert |last=Weisman |url=http://www.boston.com/business/healthcare/articles/2011/04/24/can_vertex_transform_itself_into_a_money_making_enterprise/ |newspaper=[[The Boston Globe|Boston Sunday Globe]] |date=2011-04-24
2019年9月3日福泰制药斥资9.5亿美元收购生物技术公司Semma Therapeutics。
第22行:
== 参考文献 ==
{{reflist}}
* {{cite book |url=http://investors.vrtx.com/secfiling.cfm?filingID=1047469-04-7993 |title=Annual Report |date=2004-03-15
* {{cite press release |title=Vertex Completes New Drug Application for Telaprevir for Hepatitis C |url=http://investors.vrtx.com/releasedetail.cfm?ReleaseID=532555 |publisher=Vertex Pharmaceuticals |date=2010-11-23
== 外部链接 ==
|